EuroPCR 2016: Study casts doubt on long-term TAVR durability (Dr. Danny Dvir)
Study results released this week at the annual EuroPCR conference in Paris indicated that half of transcatheter aortic valve replacements had signs of degeneration within 10 years.
The study looked at 704 patients who had a TAVR procedure between April 2002 and May 2011, following 378 of them for up to 10 years. In the 100 patients who survived for at least 5 years, there were 35 cases of valve degeneration, with a significant number showing deterioration between 5 and 7 years after TAVR implantation. The study’s authors estimated that the 8-year rate of degeneration was roughly 50%.
“Physicians performing [TAVR] in younger patients and in those expected to survive long after the procedure should be aware that the long-term rate of [transcatheter heart valve] degeneration is not negligible, at least for first-generation THV devices,” lead author Dr. Danny Dvir, of Vancouver’s St. Paul’s Hospital, said in prepared remarks. “Physicians must be mindful of the limitations of the THV they implant and whether patients can be safely treated by another transcatheter approach, such as valve-in-valve, if a THV fails years later.”
Brad Perriello reports
Angela White, St. Paul's Hospital Volunteer